Drug’s Use Broadened to Include First-Line Treatment for Involuntary Blinking – Drug for nerve pain boosts high for opioid abusers. (866) 348-2889
Officials with the FDA have expanded the indication for Merz Americas’ incobotulinumtoxinA (Xeomin) to include first-line treatment of blepharospasm in adult patients, through the approval of its supplemental Biologics License Application (sBLA).
Blepharospasm causes muscles around the eyes to contract involuntarily. Patients suffering from blepharospasm can experience symptoms that include excessive blinking, light sensitivity, dry eyes, eye irritation and watering eyes, and symptoms may worsen over time.